Santarus, Inc. (NASDAQ: SNTS), a specialty pharmaceutical company, has focused their efforts acquiring, developing and commercializing proprietary products that meet the needs of patients treated by gastroenterologists or primary care physicians. The company is currently commercializing ZEGERID® Capsules and Powder for Oral Suspension to treat upper gastrointestinal diseases and disorders, including gastroesophageal reflux disease (GERD). For further information, visit the Company’s web site at www.santarus.com.
Santarus, Inc. (NASDAQ: SNTS)
November 3, 2008 at 5:27am
Archives
Select A Month
